IN8bio/$INAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IN8bio
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
Ticker
$INAB
Sector
Primary listing
Employees
17
Headquarters
Website
IN8bio Metrics
BasicAdvanced
$14m
-
-$2.21
-
-
Price and volume
Market cap
$14m
52-week high
$4.17
52-week low
$1.17
Average daily volume
61k
Financial strength
Current ratio
10.501
Quick ratio
10.167
Long term debt to equity
5.821
Total debt to equity
10.333
Profitability
EBITDA (TTM)
-17.839
Management effectiveness
Return on assets (TTM)
-52.75%
Return on equity (TTM)
-103.55%
Valuation
Price to book
0.63
Price to tangible book (TTM)
0.63
Price to free cash flow (TTM)
-0.857
Free cash flow yield (TTM)
-116.69%
Free cash flow per share (TTM)
-1.692
Growth
Earnings per share change (TTM)
-83.36%
3-year earnings per share growth (CAGR)
-61.91%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IN8bio stock?
IN8bio (INAB) has a market cap of $14M as of May 20, 2026.
What is the P/E ratio for IN8bio stock?
The price to earnings (P/E) ratio for IN8bio (INAB) stock is 0 as of May 20, 2026.
Does IN8bio stock pay dividends?
No, IN8bio (INAB) stock does not pay dividends to its shareholders as of May 20, 2026.
When is the next IN8bio dividend payment date?
IN8bio (INAB) stock does not pay dividends to its shareholders.
What is the beta indicator for IN8bio?
IN8bio (INAB) does not currently have a Beta indicator.